12:00 AM
 | 
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Plavix clopidogrel regulatory update

FDA approved generic versions of cardiovascular drug Plavix clopidogrel. Sanofi and Bristol-Myers market the adenosine diphosphate (ADP) receptor (P2Y12) antagonist, which had U.S. sales of €4.8...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >